Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin.
SGLT2 inhibitors are a new class of oral antihyperglycaemic agents that have garnered much attention for their attractive efficacy profile in glycaemic control along with the added benefit of weight loss. There has been increasing concern for the risk of euglycaemic (serum glucose 4-8 mmol/L) ketoacidosis with these agents. In the setting of a postoperative patient, the use of these drugs may exacerbate the normal physiological stresses of the body and increase the risk of developing euglycaemic ketoacidosis (euKDA). This case highlights a postoperative patient who was using an SGLT2 inhibitor and developed severe euKDA after a pancreaticoduodenectomy. The goal of this case report was to bring awareness to the possibility of this rare adverse event. In doing so, it may aid in preoperative planning of the diabetic patient and trigger appropriate management for those who develop euKDA.
Department of General Surgery, University of Toronto, Toronto, Ontario, Canada.
Trevor
T
Wood
Department of General Surgery, University of Toronto, Toronto, Ontario, Canada.
Allison J
AJ
Pang
Department of General Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Julie
J
Hallet
Department of General Surgery, Toronto General Hospital, Toronto, Ontario, Canada.
Paul
P
Greig
Diabetes Care. 2009 Jul;32(7):1335-43
19564476
N Am J Med Sci. 2015 Jun;7(6):291-4
26199928
Diabetes Ther. 2014 Dec;5(2):355-66
25424969
Diabetes Care. 2015 Sep;38(9):1680-6
26203064
Drugs. 2015 Jan;75(1):33-59
25488697
Diabetes Care. 2015 Sep;38(9):1687-93
26078479
Diabetes Care. 2015 Sep;38(9):1638-42
26294774